FOLD Q4 2025 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$185M+23.7% YoY

Gross Profit

$157M84.6% margin

Operating Income

$16M8.6% margin

Net Income

$2M0.9% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+9.6%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$950M

Total Liabilities

$676M

Stockholders' Equity

$274M

Cash & Equivalents

$214M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$185M	$150M	+23.7%
Gross Profit	$157M	$135M	+16.2%
Operating Income	$16M	$16M	-0.2%
Net Income	$2M	$15M	-88.5%

Geographic Segments

Non-US

$85M57%

UNITED STATES

$65M43%